ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

eptinezumab

Also written as “Eptinezumab”, “ALD403” and “ALD403 (Eptinezumab)”.

Its studies are mostly in Migraine Disorders · Cluster Headache, led by 2 companies.

Drug pageEptinezumab: every studyAll 27 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Feb 23, 202223 company-led studies, 4 open or runningNext primary completion: Mar 26, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
H. Lundbeck223 open or runningphase 4since Feb 23, 2022Apr 16, 2012Mar 26, 2027phase 3 · NCT04965675
Dr George Medvedevits history only11 open or runningphase 3since May 16, 2024May 16, 2024Mar 2028phase 3 · NCT06428838

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of H. Lundbeck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 8 earlier studies, Apr 16, 2012 to Apr 3, 2020.

  1. Jun 9, 2016Named eptinezumabINNProposed as its International Nonproprietary Name in WHO's List 115 · before, ALD403
  2. Jun 3, 2020Phase 3 study in Migraine DisordersNCT04418765 · 892 enrolled · United States, Belgium, Bulgaria and more
  3. Aug 28, 2020Phase 1 study in Migraine DisordersNCT04537429 · 28 enrolled · United States
  4. Dec 24, 2020Phase 3 study in Cluster HeadacheNCT04688775 · 231 enrolled · United States, Belgium, Czechia and more
  5. Feb 23, 2021Phase 3 study in Migraine DisordersNCT04772742 · 193 enrolled · China, Georgia, Korea, Republic of and more
  6. Jun 4, 2021Phase 3 study in Migraine DisordersNCT04921384 · 981 enrolled · China, Georgia, Japan and more
  7. Jul 7, 2021Phase 3 study in Chronic Migraine in ChildrenNCT04965675 · 285 planned · United States, Argentina, Canada and more
  8. Sep 7, 2021Phase 1 study in HealthyNCT05045781 · 20 enrolled · China
  9. Sep 22, 20212 phase 3 studiesNCT05064397, NCT05064371
  10. Dec 7, 2021Phase 3 study in Migraine DisordersNCT05164172 · 600 planned · United States, Argentina, Canada and more
  11. Feb 23, 2022Phase 4 study in Migraine DisordersNCT05284019 · 32 enrolled · United States
  12. Jul 6, 2022Phase 4 study in Migraine DisordersNCT05452239 · 608 enrolled · United States, Australia, Denmark and more
  13. May 31, 2023Phase 3 study in Episodic MigraineNCT05897320 · 315 planned · United States, Argentina, Canada and more
  14. Nov 20, 2024Phase 4 study in Migraine DisordersNCT06701526 · 164 enrolled · United States
  15. Oct 16, 2026Primary completion moved from 2026-09-05 to 2027-03-26Date moved laterphase 3 · +7 months · NCT04965675

Ahead

  1. Mar 26, 2027Primary completion: phase 3 study in Chronic Migraine in ChildrenNCT04965675
  2. Jul 6, 2027Primary completion: phase 3 study in Episodic MigraineNCT05897320
  3. Apr 30, 2028Primary completion: phase 3 study in Migraine DisordersNCT05164172

TargetBeta

CALCA →CALCB →read by rule
“Calcitonin gene-related peptide inhibitor”ChEMBL 37, by rule

Studies

All 22 H. Lundbeck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06701526Migraine Disorders · United States4CompletedSep 2, 2026164
NCT05897320Episodic Migraine · United States, Argentina, Canada and more3RecruitingJul 6, 2027315
NCT05452239Migraine Disorders · United States, Australia, Denmark and more4CompletedOct 22, 2024608
NCT05284019Migraine Disorders · United States4TerminatedFeb 17, 202332
NCT05164172Migraine Disorders · United States, Argentina, Canada and more3RecruitingApr 30, 2028600
NCT05064397Cluster Headache · United States, Denmark, Finland and more3CompletedJun 29, 2023131
NCT05064371Migraine Disorders · Japan3CompletedJun 8, 2024160
NCT05045781Healthy · China1CompletedJul 20, 202120
NCT04965675Chronic Migraine in Children · United States, Argentina, Canada and more3RecruitingMar 26, 2027285
NCT04921384Migraine Disorders · China, Georgia, Japan and more3CompletedOct 1, 2024981
NCT04772742Migraine Disorders · China, Georgia, Korea, Republic of and more3CompletedMay 23, 2022193
NCT04688775Cluster Headache · United States, Belgium, Czechia and more3CompletedJun 14, 2023231
NCT04537429Migraine Disorders · United States1CompletedOct 20, 202228
NCT04418765Migraine Disorders · United States, Belgium, Bulgaria and more3CompletedJul 15, 2021892
NCT04336449Healthy · Japan1CompletedAug 13, 202018
NCT04152083Migraine Disorders · United States, Georgia3CompletedJul 8, 2020485
NCT02985398Migraine Disorders · United States3CompletedApr 2018128
NCT02974153Migraine Disorders · United States, Belgium, Czechia and more3CompletedNov 20171,121
NCT02559895Migraine Disorders · United States, Georgia3CompletedFeb 2017898
NCT02275117Migraine Disorders · United States, Australia, Georgia and more2CompletedMar 2016665
NCT01772524Migraine Disorders · United States1CompletedDec 2013163
NCT01579383Migraine Disorders · Australia1CompletedDec 2012104

How it is read

Names in the registry

  • “Eptinezumab”, 17 entries
  • “ALD403”, 5 entries
  • “ALD403 (Eptinezumab)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.